Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics to Sell $17.5M in Common Stock Through Direct Offering

NEW YORK — Cancer Genetics said on Wednesday that it has signed agreements to sell roughly $17.5 million of its common stock to unnamed institutional investors.

According to the Rutherford, New Jersey-based cancer drug-discovery services provider, it will issue approximately 2.7 million shares of stock at $6.30 apiece in a registered direct offering priced at-the-market under Nasdaq rules. It expects the offering, which is being underwritten by HC Wainwright, to close early next week.

Cancer Genetics said it will use the proceeds for general corporate purposes, including working capital and capital expenditures. The proceeds are expected to be available following the company's planned merger with Stemonix. 

Earlier this year, Cancer Genetics signed agreements to sell $10 million in stock and warrants to institutional and accredited investors. 

During mid-morning trading on the Nasdaq, shares of Cancer Genetics were down 19 percent at $6.95.

 

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.